

Special Issue

Updates on Novel Antimicrobial Agents and Strategies Against Pathogenic Bacteria

Message from the Guest Editor

The problem of antibiotic resistance in bacterial pathogens has reached alarming levels, with the emergence and diffusion at worldwide scale of strains displaying complex antibiotic resistance phenotypes which seriously impede the effective treatment of some bacterial infections. A number of international bodies, such as WHO and the American Center for Disease Control and Prevention, forecast that this 'antibiotic resistance crisis' will lead to the death of several million people per year in the 21st century. Therefore, there is an urgent need to develop novel antibiotics and innovative antimicrobial approaches. The issue aims to provide an update about original approaches to fight bacterial pathogens. It is expected that the issue will collect research articles on new molecules with antimicrobial activity, including new conventional antibiotics of either synthetic or natural origin, modified drugs with augmented potency to be used alone or in synergy, innovative alternatives such bacteriophages or components, enzybiotics, and probiotics able to displace the pathogenic microflora.

Guest Editor

Dr. Marco Maria D'Andrea

Department of Biology, University of "Tor Vergata", Rome, Italy

Deadline for manuscript submissions

closed (30 September 2019)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/24543

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)